智通财经APP讯，基石药业-B(02616)发布公告，于2025年4月25日至30日，美国癌症研究协会(AACR)年会在美国芝加哥举行。基石药业携五款自主研发的管线2.0创新产品亮相本次大会，并通过壁报展示其最新临床前研究成果，包括三抗CS2009(PD-1/VEGF/CTLA-4三特异性抗体)、双抗CS2011(EGFR/HER3双特异性抗体)及出自公司自有抗体偶联药物(ADC)平台的三款创 新ADC分 子CS5007 (EGFR/HER3 双特 异性 ADC) 、CS5005 ( ITGB4 ADC )及 CS5006(SSTR2 ADC)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.